SQLE inhibition suppresses the development of pancreatic ductal adenocarcinoma and enhances its sensitivity to chemotherapeutic agents in vitro

Fengyun Zhao1 · Yanni Huang1 · Yingheng Zhang1 · Xun Li2 · Kaizhao Chen2 · Yihao Long2 · Fugui Li3 · Xiaodong Ma2

Received: 5 February 2022 / Accepted: 22 April 2022 / Published online: 12 May 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract

Purpose In this study, we sought to explore the function of seven important enzymes (MSMO1, EBP, HMGCS1, IDI2, DHCR7, FDFT1, and SQLE) involved in cholesterol biosynthesis especially SQLE in PDAC therapy.

Methods and results The TCGA and Oncomine dataset were used to explore the expression of the seven enzymes in normal and cancerous pancreatic individual, and their anti-proliferation efficiency against PDAC cells was measured by cell viability assay. Expression level and prognostic values of SQLE were evaluated by western blot and Kaplan–Meier analysis. The influence of SQLE knockdown by shRNA in PDAC cells was assessed by transwell, colony formation and cell cycle analysis. RNA-seq and GSEA were utilized to investigate the potential mechanisms. The synergistic effect of SQLE inhibitor, terbinafine, combined with six chemotherapeutic drugs in PDAC cells was tested by CCK-8 method. We demonstrated that downregulation of those enzymes especially SQLE significantly suppressed PDAC cells survival. SQLE was upregulated in PDAC cell lines, and the elevated level of SQLE was correlated with poor prognosis in pancreatic cancer samples. SQLE knockdown could significantly inhibit the proliferation and migration of PDAC cells. Cell cycle was blocked in S phase after SQLE silencing. Mechanistically, GSEA analysis with RNA-seq data revealed that SQLE silencing negatively mediated mTORC1 and TNFα/NF-κB signaling pathways. Besides, SQLE inhibitor terbinafine enhanced chemotherapeutic sensitivity of the six compounds.

Conclusions This study demonstrated that SQLE was a novel target for PDAC therapy. The synergism role of SQLE inhibition and chemotherapy may be potential therapeutic strategy for pancreatic cancer treatment.

Keywords Pancreatic ductal adenocarcinoma (PDAC) · Squalene epoxidase (SQLE) · Cholesterol biosynthesis · mTORC1 · NF-κB

Introduction

Pancreatic ductal adenocarcinoma (PDAC) represents one of the most aggressive malignant diseases with an extremely high morbidity and mortality [1]. Surgery is the only potential curative treatment for PDAC. However, most PDAC patients are diagnosed at advanced disease stages with no opportunity for radical surgery. For advanced PDAC patients, chemotherapy is the main strategy for disease control. Despite multiple chemotherapy regimens have been applied to improve treatment outcomes over the last several decades, prognosis of PDCA remains poor, with a dismal overall 5-year survival rate of 5% [2]. Previous studies have explored therapies targeting KRAS, MAP2K4, TP53, CDKN2A, SMAD4 and TGFβR2 mutated genes, which are
recognized as major drivers of pancreatic carcinogenesis, while the results demonstrated no meaningful survival benefit in PDAC [3]. Although immune checkpoints blockade (ICB) therapy with PD-1 and PD-L1 antibodies has shown durable response rate in multiple immunogenic tumors, PDAC is not included. Hence, identification of new strategies for PDAC is urgently needed.

Recent advances in cancer metabolism have revealed that many abnormal metabolism patterns are potential targets for cancer treatment. Among various metabolic pathways, cholesterol metabolism alterations have been shown to be related to tumorigenic processes of PDAC [4]. Cholesterol is an essential substance for cell proliferation, differentiation and membrane formation, which is involved in tumor proliferation and death. In this process, cancer cells synthesize a large amount of cholesterol to meet the energetic demands associated with rapid proliferation. There are many enzymatic reactions in cholesterol metabolism. Among them, SQLE is one of the rate-limiting enzymes in the downstream of cholesterol synthesis, which catalyzes the synthesis of sterol and cholesterol from 2,3(S)-monooxidosqualene. Previous study showed that lipid metabolism was disturbed in the brain and liver of male mice with MeCP2 deficiency, and cholesterol homeostasis was considered as a potential target for Rett syndrome treatment [5]. And SQLE is highly expressed in a variety of malignant tumors, such as breast cancer [6], primary lung cancer [7, 8], prostate cancer [9], and liver cancer [10, 11]. The overexpression of SQLE can be used as a predictor of poor prognosis in breast cancer [6]. Highly expressed SQLE can inhibit the expression of PTEN and promote Akt-mTOR pathway in hepatocellular carcinoma (HCC) caused by nonalcoholic fatty liver, which is considered as an effective potential target for HCC [11]. Abnormal expression of SQLE is also proved to be a potential biomarker and therapeutic target for the treatment and prognosis of lung squamous cell carcinoma [8]. However, the specific function and mechanism of SQLE in pancreatic cancer has not been elucidated.

In this study, using loss-of-function method, we evaluated the anti-proliferation efficiency against PDAC cells of seven important enzymes involved in cholesterol metabolism, SQLE displayed significant inhibition effect on the proliferation of all the tested cell lines. The expression of SQLE was upregulated in PDAC cell lines, and the elevated SQLE levels was correlated with poor prognosis, indicating SQLE was closely related to the development of pancreatic cancer. More importantly, SQLE knockdown could significantly inhibit the proliferation and migration of PDAC cell line PANC-1. Cell cycle of PANC-1 cells was blocked in S phase after SQLE silencing. Mechanistically, GSEA analysis with RNA-seq data revealed that SQLE silencing negatively mediated mTORC1 and TNFα/NF-κB signaling pathways. Besides, the synergistic inhibition effect of terbinafine, a SQLE inhibitor, combined with six chemotherapeutic drugs (cisplatin, gemcitabine, 5-Fluorouracil, THZ1, (+)-JQ-1 and panobinostat) on the proliferation of PDAC cells was verified. Terbinafine enhanced chemotherapeutic sensitivity of all the tested compounds, especially with panobinostat. In conclusion, these findings identified SQLE as a new target for anticancer therapy in PDAC, and modulating SQLE with chemotherapeutic agents may be a potential therapeutic strategy for pancreatic cancer treatment.

Materials and methods

Cell culture and reagents

Human normal pancreatic cell line (H6C7) and PDAC cell lines (PANC-1, CFPAC1, BXPC3, PACA2, SW1990) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were incubated at 37 °C in humidified air containing 5% CO2. Panobinostat (T2383), THZ1 (T3664), Gemicitabine (T0251), (+)-JQ-1(T2110), cisplatin (T1564), 5-Fluorouracil (T0984) and terbinafine (T6702) were purchased from Target Mol (Shanghai, China).

Cell viability assay

Cell counting kit-8 (CCK-8, Dojindo) assay was applied to detect cell proliferation. Cells were inoculated in a 96-well plate at a density of 3 × 10³ cells/well. After 48 h incubation with different treatments, 10 μL CCK-8 reagent was added to each well and incubated at 37 °C for another 3 h. Subsequently, the absorbance at 450 nm of each well was determined by microplate reader. The wells were evaluated in triplicate and the experiment were repeated three times.

Colony formation assay

Cells were seeded in 6-well plates at a density of 500 cells/well and incubated at 37 °C. Cell culture medium were refreshed every 3 days until colonies formed. Following cell fixation with paraformaldehyde solution, crystal violet was utilized to stain the cells. Colonies with more than 50 cells per colony were counted under a microscope.

Transwell assay

The invasive abilities of cancer cells were tested using a 24-well transwell plate with 8 μm pore polycarbonate membrane inserts (Corning). Cells (2 × 10³) in 200 μL serum-free medium were seeded in the upper chamber and the lower
chamber was loaded with 600 μL complete medium. After cultured at 37 °C for 24 h, cells migrated to the lower membrane surface were fixed with 4% formaldehyde and stained with crystal violet. The migration of PANC-1 cells was then detected under a microscope.

Cell cycle analysis

Cells were seeded in a 6-well plate at a density of 1 × 10^6 cells/well. After different treatments, cells were harvested and fixed with 70% ethanol overnight at -20 °C. Subsequently, the fixed cells were washed twice with PBS and stained with propidium iodide (PI; BD, USA) and RNase for 25 min. Cell cycle was analyzed by flow cytometry (Accuri C6, BD Biosciences).

Plasmid construction and transfection

PANC-1, BXPC3, and CFPAC1 cells were transfected with control shRNA (shControl), SQLE shRNA (shSQLE), FDFT1 shRNA (shFDFT1), HMGCS1 shRNA (shHMGCS1), DHCR7 shRNA (shDHCR7), EBP shRNA (shEBP), MSMO1 shRNA (shMSMO1), and IDI2 shRNA (shIDI2) by using Lipofectamine RNAi MAX reagent. Briefly, 293 T cells were seeded in a 6-well plate and transfected with PRSV-rev (0.75 μg), PMDL-rre (0.75 μg), PMD2.G (0.75 μg), and shRNA plasmid (2 μg) per well. After 48 h incubation, virus supernatant was collected by centrifugation at 2000 rpm for 10 min followed by filtration through 0.45 μm filter. The PDAC cell lines were infected with 500 μL virus supernatant containing 8 μg/mL of polybrene for 6 h. Culture medium was refreshed for another 48 h of incubation, and cells were then collected for western blot analysis. The shRNA sequences for genes were as follows: shControl: 5′-GGT GTG CAG TTG GAA TGT-3′; shSQLE: 5′-GCT CAG GCT CTT TAT GAA TTA-3′; shHMGCS1: 5′-CCC ATC ATT TGG TCA ACT ATA-3′; shFDFT1: 5′-GTG TTT AAC TTC TGT GCT ATT-3′; shDHCR7: 5′-CCC TGA CTT CTG CCA TAA GTT-3′; shEBP: 5′-GCA CCT AAG ACT GGA CAA CTT-3′; shMSMO1: 5′-TGA TTT GTG GAA CCT ATT AATA-3′; shIDI2: 5′-CCT CAG GTG TTG TGT CTT TTA-3′.

Western blot

Total protein of cells was extracted using RIPA lysis buffer. Protein concentrations were determined using a BCA protein assay kit (Beyotime Biotechnology). SDS-PAGE electrophoresis was used to separate proteins. Then, the separated proteins were transferred onto the PVDF membrane, and blocked with 5% skim milk for 1 h. After that, PVDF membrane was incubated with primary antibody GAPDH (Abcam) (1:10,000) and SQLE (Proteintech) (1:2000) at 4 °C overnight. Subsequently, the membrane was incubated with HRP-conjugated anti-rabbit or murine secondary antibody (Abcam) (1:10,000) for 1 h at room temperature after being washed three times with TBST. Finally, the immunoreactive proteins were visualized with SuperSignal West Dura Chemiluminescent (Thermo Fisher).

RNA-sequencing and bioinformatics analysis

Total RNA was extracted for RNA-sequencing (RNA-Seq) by using the TRI Reagent and Direct-zol RNA kit (Zymo Research, Irvine, CA, USA) following the manufacturer’s instructions. The sequencing was performed by a sequencing service company (Novogene, Beijing, China) using the Illumina sequencing platform. Log2|Fold change|≥ 1 and P < 0.05 were used as a cut-off to define overexpression or downregulation. Gene Set Enrichment Analysis (GSEA) was then performed to reveal the signaling pathways in which differentially expressed genes were enriched.

Statistics analysis

Data are presented as mean ± SD. Data were analyzed via the Student’s t test using GraphPad Prism 8.0 software. The statistical difference P < 0.05 was considered to be significant.

Results

The role of cholesterol metabolism associated genes in cell proliferation of PDAC

Cholesterol synthesis is a complex biological process includes multiple enzymes encoded by MSMO1, EBP, HMGCS1, IDI2, DHCR7, FDFT1, and SQLE (Fig. 1A). To explore their roles in pancreatic cancer, we first analyzed their expression in PDAC by using ONCOMINE and TCGA database. As shown in Fig. 1B and C, only SQLE and MSMO1 were significantly overexpressed in pancreatic tumor tissues compared to their adjacent tissues or normal tissues. To further investigate the function of these 7 genes in multiple PDAC cell lines including PANC-1, CFPAC1 and BXPC3, we constructed shRNA to knockdown these genes in cell lines, and evaluated cell proliferation at 24, 48 and 72 h after gene silencing. Our results showed that knocking down these genes in these PDAC cell lines significantly suppressed cell proliferation (Fig. 1D–F). In particular, knockdown of SQLE displayed most significant inhibition effect on the proliferation than other 6 genes. Thus, we focused on SQLE in the further experiments.
SQLE is up-regulated and promotes tumor progression in PDAC

To explore the expression signature of SQLE, we first evaluated the transcription level of SQLE in human normal tissues from GTEx. And the data showed that SQLE level was highly abounded in esophagus, brain and skin tissue, while it represented a relative low expression in muscle, heart and pancreatic tissues (Fig. 2A). Next, we evaluated the expression of SQLE in multiple solid tumors based on the TCGA database, and the result showed that SQLE was overexpressed in most solid tumors including PDAC, which indicated the critical role of SQLE in tumorigenesis (Fig. 2B). To confirm these findings, the expression of SQLE in six pancreatic cancer cell lines, PANC-1, BXPC3, CFPAC1, ASPC1, SW1990 and PACA2 was measured by western blot, with pancreatic duct epithelial cell (H6C7) as control group. The results indicated that SQLE expression level was significantly increased in pancreatic cancer cell lines compared with H6C7 (Fig. 2C). Moreover, PDAC patients with higher SQLE expression had shorter overall survival than that with lower SQLE expression (Fig. 2D). To explore the potential role of SQLE in cell proliferation and migration of PDAC, lentivirus-delivered SQLE shRNA vector (shSQLE) and control shRNA vector (shControl) were constructed and were transfected into PANC-1 and CFPAC1 cells. As shown in Fig. 2E, shSQLE remarkably decreased the expression of SQLE in both PANC-1 and CFPAC1 cell lines. The colony formation assays showed that silencing SQLE in PANC-1 and CFPAC1 cells significantly reduced the number of colonies (Fig. 2F). Next, we measured the cell migration of PANC-1 via transwell assay. Knockdown of SQLE inhibited the cellular migration of PANC-1 cells (Fig. 2G). Moreover, PANC-1 cells steady transfected with shSQLE showed an increase in S phase cell population and a decrease in G1 phase cell population (Fig. 2H). Taken together, these observations indicated up-regulated SQLE expression promoted tumor progression in PDAC and was associated with poor prognosis in patients.

SQLE silencing negatively modulates mTORC1 and TNFa/NF-κB signaling in pancreatic cancer cells

To explore the mechanism underlying SQLE silencing in PDAC cell proliferation, we performed RNA-sequencing (RNA-seq) on PANC-1 cells transfected with shControl or shSQLE. A total of 1023 differently expressed genes (DEGs) were identified (Fig. 3A). Gene Set Enrichment Analysis (GSEA) revealed the most enriched canonical pathways involved in the mTORC1 signaling and TNFa/
NF-κB signaling (Fig. 3B–D). These findings indicated that SQLE silencing negatively mediated mTORC1 and TNFα/NF-κB signaling pathway to suppress pancreatic cancer cells proliferation.

Fig. 2 SQLE is upregulated and promotes tumor progression in PDAC. A The transcription levels of SQLE in human normal tissues from GTEx. B The mRNA expression of SQLE between tumor and normal samples from TCGA. C The protein expression level of SQLE in normal pancreatic cell line (H6C7) and pancreatic cancer cell lines PANC1, BXP3, CFPAC1, ASPC1, SW1990 and PACA2. D Kaplan–Meier analysis (log-rank test) of overall survival of human pancreatic cancer samples from Kaplan–Meier Plotter database based on SQLE expression. E Knockdown of SQLE in PANC-1 and CFPAC1 cells was confirmed by Western blot. F The effect of knocking down SQLE on colony formation in Panc-1 and CFPAC1 cells was tested using a colony formation assay. Colonies consisting of more than 50 cells were counted by microscope with ×10 objective. G The effect of knocking down SQLE on cell invasive ability in Panc-1 cells was tested using a transwell migration assay, Scale bars, 100 μm. H Cell cycle distribution was determined using propidium iodide (PI) staining and analyzed by flow cytometry after PANC-1 cells steadily transfected with shControl or shSQLE. *P < 0.05, **P < 0.01, ***P < 0.001

SQLE inhibition enhances chemotherapeutic sensitivity in PDAC cell lines

Given the important oncogenic role of SQLE in PDAC, we
evaluated whether SQLE silencing have synergistic effect on the inhibition of PDAC cells proliferation in combined with chemotherapeutic agents. Six chemotherapeutic compounds including cisplatin, gemcitabine, 5-Fluorouracil (5FU), THZ1, (+)-JQ-1 (JQ1) and panobinostat were used. The results showed that knockdown of SQLE by shSQLE significantly enhanced the inhibition effect of PANC-1 cells proliferation induced by chemotherapeutic compounds (Fig. 4A). Terbinafine is an FDA-approved antifungal drug, which targets SQLE. We next evaluated the viability of PANC-1 cells treated with terbinafine combined with different doses of other six chemotherapeutic compounds. The combined therapy of terbinafine with those chemotherapeutic drugs markedly enhanced the inhibition of cell multiplication compared with therapies using either of these drugs alone, and the results indicated terbinafine had a strongest synergistic interaction with panobinostat (Fig. 4B). To further validate the effective synergism role of terbinafine and panobinostat in PDAC, we further tested the synergistic effect of terbinafine and panobinostat combined therapy in other PDAC...
cell lines (PACA2, SW1990, CFPAC1, BXPC3, ASPC1). The results showed that the combination of terbinafine and panobinostat had synergistic effects on the inhibition of cell multiplication in all of these PDAC cell lines (Fig. 4C). Collectively, these results suggested that the combination of SQLE inhibitor with chemotherapeutic compounds could be a potential therapeutic strategy for PDAC treatment.

**Discussion**

Pancreatic cancer especially PDAC is a fatal malignant disease with extremely low expectancy. There are no effective options for PDAC treatment besides surgical therapy. But PDAC patients usually have no chance to surgery, which results in rather low overall survival rate and poor prognosis. Therefore, identifying novel therapeutic targets are potential strategies for improving survival rate of PDAC patients.

In the past several years, many studies have recognized that cholesterol metabolism played a critical role in the development of PDAC [12, 13]. Cholesterol is not only the essential constituent for maintaining cell homeostasis, but also an important component of plasma membrane [14]. Among numerous enzymes regulating the complex process of cholesterol synthesis, SQLE is one of the most important rate-limiting enzymes [15, 16]. SQLE participates in catalyzing the second rate-controlling step in cholesterol biosynthesis and metabolism [17]. Increasingly studies have reported that dysregulation of SQLE was observed in different malignant tumors, including breast cancer [6], hepatocellular carcinoma [10], squamous cell carcinoma [7] and prostate cancer [9]. Thus, SQLE is an important target in a variety of tumors.

In this study, we identified SQLE as a novel target in PDAC treatment. We found that compared with other genes that modulating cholesterol metabolism, SQLE was remarkably overexpressed in pancreatic cancer cell lines. To evaluate the clinical significance of SQLE in PDAC, we performed the overall survival analysis based on SQLE expression level. The result revealed that high SQLE expression was correlated with poor prognosis in PDAC.

Moreover, SQLE silencing in PANC-1 cells significantly inhibited cell proliferation and migration, blocked the cell cycle in S phase. These findings indicated that SQLE was a potential target for PDAC therapy.
Previous studies have shown that overexpressed SQLE in HCC inhibited the expression of PTEN, leading to the enhancement of tumor cell proliferation and promotion of tumor development [10]. Abnormal expression of SQLE in primary invasive breast cancer is related to the activation of MYC [5] and cancer-associated microprotein CASIMO1, which interacts with SQLE in modulating lipid droplet formation [18]. SQLE has also been reported to promote the development of lung squamous cell carcinoma by activating ERK signaling pathway [7]. In addition, it was revealed that SQLE could induce epithelial to stromal transformation by regulating miR-133b in esophageal squamous cell carcinoma [19]. Furthermore, recent studies showed that reduction or loss of SQLE protected the cancer cells in lymphoma [20] and colorectal cancer [21]. In the present study, we found upregulated SQLE expression promoted tumor progression and its expression level was associated with poor prognosis in pancreatic cancer patients. Thus, we silenced SQLE expression in PANC-1 cells and RNA-seq data analysis by GSEA demonstrated that SQLE silencing could negatively regulate mTORC1 and TNFα/NF-κB signaling pathway. Besides, knockdown of SQLE could enhance the sensitivity of PANC-1 cells to chemotherapeutic drugs. As expected, the combination of SQLE inhibitor terbinafine and chemotherapeutic drugs improved the curative effect and achieve a synergistic effect, and the combination of terbinafine and panobinostat had strongest synergistic effects in all of the tested PDAC cell lines, which provided a potential treatment strategy for PDAC. However, there are still some limitations in this study. Firstly, the effect of SQLE knockdown on PDAC tumor proliferation in vivo required to be verified in the future. Secondly, the mechanism of SQLE inhibition negatively regulates mTORC1 and TNFα/NF-κB signaling pathway is also need to be further investigated.

Conclusions

In summary, this study demonstrates that SQLE is a novel target for PDAC therapy. The synergism role of SQLE inhibition and chemotherapy may be potential therapeutic strategies for pancreatic cancer treatment.

Acknowledgements This work was supported by National Natural Science Foundation of China (Grant Nos. 81772533, 81773249, 82072697) and the Public Welfare Scientific Research Project of Zhongshan City (No. 2019B1015).

Author contributions ZF, YNH and YHZ performed most experiments. LX, CK, LYY assisted in flow cytometry, Western blot analysis, and data interpretation. MX and FGL designed and wrote the manuscript. All authors reviewed the manuscript and approved the submission.

Data availability The RNA-seq data that support the findings of this study are openly available in figshare at http://doi.org/10.6084/m9.figshare.16740286.

Declarations

Conflict of interest All authors declared that they have no competing interests.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication All authors agreed with the content of the manuscript.

References

1. Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22(44):9694–9705
2. Castaneda-Avila M, Cruz-Benitez A, Fuentes-Payán W, Malondo-Albertorio A, Nieves-Ferrer L, Padro-Juarbe P et al (2016) Epidemiology of pancreatic cancer in Puerto Rico (1987–2010): incidence mortality and survival. Austin J Gastroenterol 3(1):1058
3. Goral V (2015) Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev 16(14):5619–5624
4. Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY et al (2021) Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J Gastroenterol 27(27):4298–4321
5. Parris TZ, Koivs A, Hajizadeh S, Nemes S, Semaan M, Levin M et al (2014) Frequent MYC coamplification and DNA hypomethylation of multiple genes on 8q in 8p11-p12-amplified breast carcinomas. Oncogenesis 3:e95
6. Brown DN, Caffa I, Cirmena G, Piras D, Garuti A, Gallo M et al (2016) Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. Sci Rep 6:19435
7. Ge H, Zhao Y, Shi X, Tan Z, Chi X, He M et al (2019) Squalene epoxidase promotes the proliferation and metastasis of lung squamous cell carcinoma cells though extracellular signal-regulated kinase signaling. Thorac Cancer 10(3):428–436
8. Liu Y, Sun W, Zhang K, Zheng H, Ma Y, Lin D et al (2007) Identification of genes differentially expressed in human primary lung squamous cell carcinoma. Lung Cancer 56(3):307–317
9. Khan NA, Stoppsack KH, Allott EH, Gerke T, Giovannucci EL, Mucci LA et al (2019) Intratumoral sterol-27-hydroxylase (CYP27A1) expression in relation to cholesterol synthesis and vitamin D signaling and its association with lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 28(6):1052–1058
10. Sui Z, Zhou J, Cheng Z, Lu P (2015) Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells. Tumour Biol 36(8):6173–6179
11. Liu D, Gong CC, Fu L, Chen H, Zhao L, Li C et al (2018) Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aap9840
12. Guillammond F, Bidaud G, Ouaisi M, Servais S, Gouriand V, Olivares O et al (2015) Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci USA 112(8):2473–2478
13. Gupta VK, Sharma NS, Kesh K, Dauer P, Nomura A, Giri B et al (2018) Metastasis and chemoresistance in CD133 expressing
pancreatic cancer cells are dependent on their lipid raft integrity. Cancer Lett 439:101–112
14. Ikonen E (2008) Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 9(2):125–138
15. Chua NK, Coates HW, Brown AJ (2020) Squalene monooxygenase: a journey to the heart of cholesterol synthesis. Prog Lipid Res 79:101033
16. Gill S, Stevenson J, Kristiana I, Brown AJ (2011) Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. Cell Metab 13(3):260–273
17. Bonne AC, den Bieman MG, Gillissen GF, van Lith HA, van Zutphen LF (2002) Chromosomal localization of genes involved in biosynthesis, metabolism or transport of cholesterol in the rat. Cytogenet Genome Res 97(3–4):183–186
18. Polycarpou-Schwarz M, Gross M, Mestdagh P, Schott J, Grund SE, Hildenbrand C et al (2018) The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene 37(34):4750–4768
19. Qin Y, Zhang Y, Tang Q, Jin L, Chen Y (2017) SQLE induces epithelial-to-mesenchymal transition by regulating of miR-133b in esophageal squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai) 49(2):138–148
20. Garcia-Bermudez J, Baudrier L, Bayraktar EC, Shen Y, La K, Guarecuco R et al (2019) Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. Nature 567(7746):118–122
21. Jun SY, Brown AJ, Chua NK, Yoon JY, Lee JJ, Yang JO et al (2021) Reduction of squalene epoxidase by cholesterol accumulation accelerates colorectal cancer progression and metastasis. Gastroenterology 160(4):1194–1207

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.